Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875176 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL29870420 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL26299278 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661021 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL851826 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661377 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL101673 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL6555279 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL660625 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL16559904 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| WO-2023144053-A1 | HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-03 | — | — | WO | disclosed |
| US-20230084927-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD. (IL) | 2023-03-16 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| CN-107567442-B | Inhibitors of hepatitis C virus polymerase | 共晶制药公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| WO-2013044361-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-04-04 | — | — | WO | disclosed |
| US-20120042778-A1 | SULFUR DIOXIDE ABSORBENT COMPRISING IONIC LIQUID | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-02-23 | — | — | US | disclosed |
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | JAMES KENNETH D | 2010-08-26 | — | — | US | disclosed |
| US-7648962-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-01-19 | — | — | US | disclosed |
| US-20080207505-A1 | Bna Conjugates and Methods of Use | JAMES KENNETH D | 2008-08-28 | — | — | US | disclosed |
| EP-0745894-B1 | Black and white photographic elements containing release compounds and method of preparing photographic emulsion | EASTMAN KODAK CO (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-0745894-A1 | Black and white photographic elements containing release compounds and method of preparing photographic emulsion | EASTMAN KODAK COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5500338-A | Black and white photographic elements containing release compounds and method of preparing photographic emulsion | EASTMAN KODAK COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207505-A1 | Bna Conjugates and Methods of Use | NPR1, NPPA, NPR3 | USP2 4180/4885TSHR 327/4885KDM4E 4280/4885 |
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | MTTP, CETP, LNPEP | USP2 3280/4885TSHR 1569/4885KDM4E 622/4885 |
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | PRDX5, ANXA5, PRDX1 | USP2 3339/4885TSHR 3527/4885KDM4E 4234/4885 |
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NPR1, NPPA, NPR3 | USP2 4311/4885TSHR 261/4885KDM4E 4548/4885 |
| US-20120042778-A1 | SULFUR DIOXIDE ABSORBENT COMPRISING IONIC LIQUID | TST, CBS, ARSA | USP2 1241/4885TSHR 1824/4885KDM4E 1504/4885 |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | USP2 3328/4885TSHR 63/4885KDM4E 3952/4885 |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | USP2 1327/4885TSHR 766/4885KDM4E 3367/4885 |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | POLI, POLR2E, POLR2H | USP2 3680/4885TSHR 4606/4885KDM4E 3514/4885 |
| US-20230084927-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | SLC2A4, SLC2A1, SLC2A2 | USP2 2958/4885TSHR 243/4885KDM4E 2887/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | USP2 3328/4885TSHR 63/4885KDM4E 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.